Wegovy tablets received UK approval on 11 June 2026, when the MHRA authorised oral semaglutide for adult weight management. The announcement covers a prescription medicine used alongside reduced-calorie eating and increased physical activity.

An oral option may matter to someone who finds injections difficult, but it still has specific administration requirements and risks. Tablet and injection formulations should not be treated as freely interchangeable.

Who does the UK Wegovy tablet approval cover?

The authorisation covers adults with BMI of at least 30, or BMI of at least 27 with a weight-related health condition. In the OASIS 4 trial, estimated mean weight change at 64 weeks was −13.6% with oral semaglutide versus −2.2% with placebo under the treatment-policy analysis. Different analyses can produce different headline percentages; trial averages are not personal predictions.

At the time of the MHRA announcement, the tablets were not available through the NHS and assessment through established NHS processes, including NICE evaluation, remained necessary. That dated announcement does not establish present stock, private prices or a current NHS entitlement. Ask the relevant prescriber or service about availability.

Wegovy tablets: administration and side effects

  • Follow the patient leaflet for the tablet formulation; its fasting and absorption requirements matter.
  • Common side effects include nausea, diarrhoea, constipation and vomiting.
  • Discuss side effects with a healthcare professional and report suspected reactions through the MHRA Yellow Card scheme.

How an oral option fits into wider support

Healthcare professionals emphasise that while oral weight-loss medication may enhance accessibility and ease of use, it is not a standalone solution. Weight-loss drugs should be integrated into broader strategies involving nutrition, physical activity, and behavioural support.

Experts also highlight the need for continued public health efforts addressing the wider environment influencing obesity, including food systems and lifestyle factors.

Reading approval and access news accurately

An approval announcement explains what a medicine may be prescribed for. It does not guarantee that a service supplies it or that it is suitable for a particular person. This article is educational and does not provide a switching schedule or treatment recommendation. More Svelta Labs resources are available at https://sveltalabs.com.

Sources

MHRA: Wegovy tablet approval, 11 June 2026: https://www.gov.uk/government/news/first-glp-1-tablet-for-weight-loss-approved-in-the-uk.

NEJM: OASIS 4 oral semaglutide trial: https://www.nejm.org/doi/10.1056/NEJMoa2500969.

MHRA: Yellow Card reporting: https://yellowcard.mhra.gov.uk/.